MCRB - Seres Therapeutics falls 9% on full-year earnings miss
2023-03-07 12:20:01 ET
- Seres Therapeutics ( NASDAQ: MCRB ) is trading ~9% lower premarket after the company missed revenue and GAAP EPS estimates, as costs rose.
- Seres Therapeutics FY GAAP EPS of -$2.31 missed by $0.15, while revenue fell 95.5% to $7.13M, and missed estimates by $6.62M.
- Q4 Research and development expenses rose to $46.2M vs $36.8M, a year earlier.
- Q4 general and administrative expenses rose to $22.4M vs $20.5M, a year earlier, due to personnel expenses, professional fees, including SER-109 commercial readiness and pre-launch expenses, and facility costs.
For further details see:
Seres Therapeutics falls 9% on full-year earnings miss